Life & Health R&D Forum: translational medicine in focus

05 Jun 2013

Location: Singapore-ETH Centre (SEC), Singapore

About the event

Swiss Re, one of the world’s largest re/insurers, in collaboration with swissnex Singapore, one of five Swiss science and technology consulates worldwide, cordially invite you to this interactive half-day conference, to be held at the Future Cities Laboratory at the Singapore-ETH Centre (SEC) in Singapore. This is the second event in collaboration with swissnex Singapore and SEC after last year's The future of human longevity: new approaches to healthcare and cancer.


With the increase in molecular understanding of disease, translational medicine has become center-stage. The output from emerging approaches is remarkable and has profoundly changed the way in which we treat people. We will address diseases such as dementia, Alzheimer's, cancer, cardiovascular and tropical diseases, discuss the key challenges that need to be overcome for new approaches to succeed, and learn about early successes and the impact they may have on future mortality.

Target audience

Leading experts in fields spanning epidemiology, the ageing process, and cutting edge advances in the prevention, detection and treatment of disease, and insurance industry representatives heading mortality and longevity research / pricing units.

Note: This event may be photographed, filmed and /or recorded. A summary of the event, pictures and/or a video of the event in which you may appear may be posted and made available on Swiss Re’s and swissnex Singapore's internal and external websites and in printed materials.


Wednesday, 5 June 2013

Time difference compared to Central European Time: -6 hours


Welcome coffee and registration


Suzanne Hraba-Renevey, Director, swissnex Singapore
Remo Burkhard, Managing Director, Singapore-ETH Centre (SEC)


Translational medicine: from bench to bedside
Christoph Nabholz, Head Business Development, Swiss Re Centre for Global Dialogue


Novel therapeutics in the pharma pipeline
Severine Rion, Senior Pharmacist, Life & Health R&D, Swiss Re


Translational medicine in practice
Mark Jurgens, Head, Roche Singapore Translational Medicine Hub


Coffee break


Molecular approaches to the diagnosis and treatment of Alzheimer's disease
Christopher Chen, Senior Clinician-Scientist, National Medical Research Council of Singapore; Associate Professor, Faculty of Medicine, National University of Singapore


Recent medical advances in cardiovascular disease treatment
Detloff Rump, Chief Underwriter Asia, Swiss Re


Novel approaches to treat tropical diseases
Thierry Diagana, Head, Novartis Institute for Tropical Diseases (NITD)





Translational medicine is one of the leading current areas of medical research. It seeks to understand the molecular causes behind diseases and create subsequent treatments. Rather than study disease by observable symptoms, as traditional medicine has done, translational medicine provides greater insight into the many molecular pathways which may cause a particular illness. This, in turn, has the potential to allow for treatments specific and tailored to the individual - hence the term personalised medicine, often used in conjunction with translational medicine.

It is still early days for translational medicine. Its potential, however, is significant. It can make and is starting to make an appreciable improvement in quality of lives for many. Equally, it has the potential to shift mortality rates. This makes it of great interest to the re/insurance industry, both in terms of health coverage, as well as in life and health lines. It is in this spirit that Swiss Re invited stakeholders from across the medical research industry – from academia, major pharmaceutical companies, the insurance industry, and other stakeholders – to further discuss these novel disease pathways and the potential health impact of new diagnostics, drugs and medical devices that are derived from them.

To read the entire summary, please click here.